Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Margaret T. Wecker"'
Autor:
David C. Korts, Paul Koker, Louis Diamond, Martin Posner, James C. Kisicki, Miguel A. Zinny, Dockhorn Rj, J Grossman, Margaret T. Wecker
Publikováno v:
Journal of Allergy and Clinical Immunology. 95:1139-1146
Rhinorrhea is an annoying symptom of the common cold for which effective therapy is not currently available. Ipratropium bromide (IB) is an anticholinergic drug that has been shown to decrease glandular secretion when applied topically to the nasal m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3306eb6db2b8110521dcf0194855a5c3
https://doi.org/10.1016/s0091-6749(95)70219-9
https://doi.org/10.1016/s0091-6749(95)70219-9
Publikováno v:
American journal of rhinology. 12(2)
The topical anticholinergic ipratropium bromide and topical decongestant oxymetazoline were tested to determine whether oxymetazoline alone and the combination were well tolerated and reduced rhinorrhea and middle ear pressure abnormalities during ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d47723b8a78f5d45dd0df2d66423e2b6
https://pubmed.ncbi.nlm.nih.gov/9578931
https://pubmed.ncbi.nlm.nih.gov/9578931
Publikováno v:
Annals of internal medicine. 125(2)
OBJECTIVE To determine the tolerability and clinical effectiveness of intranasal ipratropium bromide for the treatment of symptoms of common colds. DESIGN Multicenter, double-blind, randomized trial. SETTING 3 university student health services. PATI
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32500ff6b887c4a1ef121619f077b64c
https://pubmed.ncbi.nlm.nih.gov/9005758
https://pubmed.ncbi.nlm.nih.gov/9005758
Publikováno v:
The Journal of allergy and clinical immunology. 95(5 Pt 2)
The in vivo absorption potential of ipratropium bromide nasal spray was evaluated in studies involving healthy volunteers (0.03%, 0.06%, and 0.12% dosage strengths) and patients with perennial rhinitis (0.03% and 0.06%) and the common cold (0.06%). T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0a45b3da9ef16b0aa3dbf5fbdd4215f
https://pubmed.ncbi.nlm.nih.gov/7751527
https://pubmed.ncbi.nlm.nih.gov/7751527
Autor:
Eugene McNally, Margaret T. Wecker, Frederick G. Hayden, Roger St. George, Theodore J. Witek, Ronald B. Turner, Birgit Winther, Gerhardt Pohl
Publikováno v:
JAMA. 281:1797
ContextAttachment of most rhinovirus subtypes to cells depends on a cellular receptor, the intercellular adhesion molecule 1 (ICAM-1). A recombinant soluble ICAM-1 (tremacamra, formerly BIRR 4) has shown possible efficacy in early studies.ObjectiveTo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f2ec65cd52eaa4bc056133f6464a82b
https://doi.org/10.1001/jama.281.19.1797
https://doi.org/10.1001/jama.281.19.1797
Publikováno v:
Journal of Pharmaceutical Sciences. 76:29-31
The influence of a standard meal on the extent and rate of absorption of pseudoephedrine from a controlled-release (CR) capsule formulation (Pennkinetic System) was studied in 16 normal male volunteers. Equivalent single doses of an immediate-release
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7056224883275e635ccb6d83d773473
https://doi.org/10.1002/jps.2600760109
https://doi.org/10.1002/jps.2600760109